Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012
DateTitle 
May 10, 2019BioTime Awarded $2.5 Million Grant from the Israel Innovation Authority for Continued Development of OpRegen®
ALAMEDA, Calif.--(BUSINESS WIRE)--May 10, 2019-- BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet medical needs, has been awarded a new research & development grant for 2019 of up to 9 million Israeli New Shekels (approximately $2.5 million USD) from the Israel Innovation Authority (the “IIA”). The grant provides funding for the continued development of OpRegen®, the Co... 
Printer Friendly Version
May 09, 2019BioTime Reports First Quarter 2019 Financial Results and Provides Business Update
Positive OpRegen® Data Presented at Association for Research in Vision and Ophthalmology Annual Meeting Announced Issuance of New Patent for Method of Reducing Cavitation in Patients with Acute Spinal Cord Injury Entered Into Exclusive Collaboration with Orbit Biomedical Ltd. ALAMEDA, Calif.--(BUSINESS WIRE)--May 9, 2019-- BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnolog... 
Printer Friendly Version
May 06, 2019BioTime Announces Issuance of U.S. Patent for Method of Reducing Cavitation in Patients with Acute Spinal Cord Injury
ALAMEDA, Calif.--(BUSINESS WIRE)--May 6, 2019-- BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet needs, announced today the issuance of a Notice of Allowance for a patent from the United States Patent and Trademark Office (USPTO) for United States Patent Application No. 15/156,316 for a method of reducing spinal cord injury (SCI)-induced parenchymal cavitation in patients t... 
Printer Friendly Version
May 03, 2019BioTime to Report First Quarter 2019 Financial Results and Provide Business Update on May 9, 2019
ALAMEDA, Calif.--(BUSINESS WIRE)--May 3, 2019-- BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing new cellular therapies, today announced that it will report its first quarter 2019 financial and operating results on Thursday, May 9th, 2019, following the close of the U.S. financial markets. BioTime management will also host a conference call and webcast on Thursday, May 9th, 2019, at 4:30 p.m. Eastern ... 
Printer Friendly Version
May 02, 2019BioTime Presents Updated Data from OpRegen® Phase I/IIa Clinical Study at the Association for Research in Vision and Ophthalmology Annual Meeting
Treatment with OpRegen® Continues to be Well Tolerated with Signs of Structural Improvement in the Retina Observed in Some Patients ALAMEDA, Calif.--(BUSINESS WIRE)--May 2, 2019-- BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing new cellular therapies, announced that updated results from a Phase I/IIa clinical study of its lead product candidate, OpRegen®, a retinal pigment epithelium (RPE) ... 
Printer Friendly Version
April 26, 2019BioTime to Present SCiStar Clinical Study Top-Line Data at the 26th Annual American Society for Neural Therapy and Repair Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 26, 2019-- BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing new cellular therapies, announced today that Edward D. Wirth, III, M.D., Ph.D., Chief Medical Officer of BioTime, will present at the 26th Annual American Society for Neural Therapy and Repair (ASNTR) Annual Conference on April 26th, 2019 at 10:30am EDT as part of Session 6: “Spinal Cord Injury”. D... 
Printer Friendly Version
April 16, 2019BioTime to Present Data from OpRegen® Phase I/IIa Clinical Study at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2019)
ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 16, 2019-- BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing new cellular therapies, announced today that updated results from a Phase I/IIa clinical study of its lead product candidate, OpRegen®, a retinal pigment epithelium (RPE) cell transplant therapy currently in development for the treatment of dry age-related macular degeneration (AMD) with geographic atroph... 
Printer Friendly Version
March 18, 2019BioTime to Present at Oppenheimer & Co. 29th Annual Healthcare Conference on March 20, 2019
ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 18, 2019-- BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that Brian M. Culley, Chief Executive Officer, will be presenting at the Oppenheimer & Co. 29th Annual Healthcare Conference on March 20th, 2019 at 2:45pm Eastern Time at the Westin New York Grand Central in the Track 2 Room in New York, NY. Intere... 
Printer Friendly Version
March 14, 2019BioTime Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
Completed Acquisition of Asterias Biotherapeutics, Inc. Completed Distribution of AgeX Therapeutics Shares to BioTime Shareholders Entered Into Exclusive Collaboration with Orbit Biomedical Ltd. ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 14, 2019-- BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, reported financial and operating resul... 
Printer Friendly Version
March 11, 2019BioTime Announces Closing of Acquisition of Asterias Biotherapeutics Creating Leading Cell Therapy Company
Company Will Advance Three Clinical Stage Product Candidates Addressing Significant Unmet Needs in Dry-AMD, Spinal Cord Injury, and Immuno-Oncology ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 11, 2019-- BioTime, Inc. (NYSE American and TASE: BTX), today announced the closing of its previously reported acquisition of Asterias Biotherapeutics, Inc. (Asterias), whereby BioTime has acquired through a merger, all of the remaining outstanding comm... 
Printer Friendly Version
March 07, 2019BioTime to Report Fourth Quarter and Full Year 2018 Financial Results on March 14th, 2019
ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 7, 2019-- BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it will report its fourth quarter and full year 2018 financial and operating results on Thursday, March 14th, 2019, following the close of the U.S. financial markets. BioTime management will also host a conference call and webcast on Thursday, March 14th, 2019, a... 
Printer Friendly Version
March 04, 2019BioTime to Present at the 14Th Annual Scientific Meeting of the Association for Ocular Pharmacology and Therapeutics (AOPT 2019) on March 10, 2019
ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 4, 2019-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, announced today that Francois Binette, PhD, Senior Vice President and Global Head of Product Development at BioTime, Inc., will present the 14th Annual Scientific Meeting of the Association For Ocular Pharmacology and Therapeutics (AOPT 2019) on March 10, 2019 at 1pm EDT, as part of Se... 
Printer Friendly Version
February 26, 2019BioTime to Present New Data From OpRegen® and Vision Restoration Programs at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2019)
ALAMEDA, Calif., Feb. 26, 2019 (GLOBE NEWSWIRE) -- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, announced today that updated results from a Phase I/IIa study of its lead product candidate, OpRegen®, a retinal pigment epithelium (RPE) cell transplant therapy currently in development for the treatment of dry age-related macular degeneration (Dry-AMD), will be presented at the 2019 Association for Research in Vision and Ophthalmology... 
Printer Friendly Version
February 14, 2019BioTime Provides Business Update Including Information on AgeX, OncoCyte and Asterias
ALAMEDA, Calif., Feb. 14, 2019 (GLOBE NEWSWIRE) -- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today provided a business update which included information on AgeX Therapeutics, Inc. (AgeX) (NYSE American: AGE) and BioTime’s two affiliated companies, OncoCyte Corporation (OncoCyte) (NYSE American: OCX), and Asterias Biotherapeutics, Inc. (Asterias) (NYSE American: AST). “In the past five months, BioTime has made rapid progress ... 
Printer Friendly Version
January 30, 2019BioTime Inc. Affiliate Company OncoCyte Corporation Reports Successful Results With DetermaVu™ Diagnostic Test for Lung Cancer
ALAMEDA, Calif., Jan. 30, 2019 (GLOBE NEWSWIRE) -- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that its affiliate company, OncoCyte Corporation (OncoCyte) (OCX), a developer of novel, non-invasive tests for the early detection of cancer, has reported positive results from an R&D validation study of DetermaVu™, a non-invasive, liquid biopsy test intended to facilitate clinical decision making in lung cancer dia... 
Printer Friendly Version
January 07, 2019BioTime Enters Into Exclusive Agreement With Orbit Biomedical Ltd. to Access Innovative Device for the Sub-Retinal Delivery of OpRegen® Cells for the Treatment of Dry-AMD
ALAMEDA, Calif., Jan. 07, 2019 (GLOBE NEWSWIRE) -- BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it has entered into a research and option agreement with Orbit Biomedical Limited (“Orbit Biomedical”).  Orbit Biomedical, based in London, UK and Ambler, PA, was founded in 2018 to develop a surgical device and training platform for the delivery of cell and gene therapies to the sub-retinal space.  Under t... 
Printer Friendly Version
January 04, 2019BioTime Announces Management Changes Concurrent With Participation at 2019 J.P. Morgan Healthcare Conference and 2019 Biotech Showcase
ALAMEDA, Calif., Jan. 04, 2019 (GLOBE NEWSWIRE) -- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced the appointment of Brandi L. Roberts, M.B.A. as Chief Financial Officer and Senior Vice President, Finance, effective January 7, 2019. Ms. Roberts brings more than 23 years of public accounting and finance experience, including 20 years at publicly traded pharmaceutical, medical technology, and life science companies.  M... 
Printer Friendly Version
January 02, 2019BioTime to Present at 2019 Biotech Showcase Investor Conference on January 7, 2019
ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 2, 2019-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that Brian M. Culley, Chief Executive Officer of BioTime will be presenting at the 2019 Biotech Showcase Investor Conference on January 7th, 2019 at 9am Pacific Time at the Hilton San Francisco Union Square Hotel in the Franciscan A Ballroom in San Francisco, CA. ... 
Printer Friendly Version